APA

Mavratzas A., Baek S., Gerber B., Schmidt M., Moebus V., Foerster F., Grischke E. M., Fasching P., Strumberg D., Solomayer E., Klare P., Windemuth-Kieselbach C., Hartmann S., Schneeweiss A. & Marmé F. (20191203). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. : Breast (Edinburgh, Scotland).

Chicago

Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke E M, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A and Marmé F. 20191203. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. : Breast (Edinburgh, Scotland).

Harvard

Mavratzas A., Baek S., Gerber B., Schmidt M., Moebus V., Foerster F., Grischke E. M., Fasching P., Strumberg D., Solomayer E., Klare P., Windemuth-Kieselbach C., Hartmann S., Schneeweiss A. and Marmé F. (20191203). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. : Breast (Edinburgh, Scotland).

MLA

Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke E M, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A and Marmé F. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. : Breast (Edinburgh, Scotland). 20191203.